Biopharma financings from January through September 2025 totaled $47.1 billion, a sharp decline from 2024’s $86.7 billion during the same period and well below the highs of 2020 and 2021. The slowdown ...

The U.S. FDA device center’s guidance agenda for fiscal 2026 is the classic case of something old and something new, but what ...

Nanyang Biologics Pte. Ltd. has entered a $1.5 billion business combination agreement with RF Acquisition Corp II, a ...

Bacterial resistance remains one of the biggest obstacles to antibiotic efficacy and spurs the constant search for ...

The U.S. FDA has approved the priority sNDA for a new first-line maintenance therapy in extensive-stage small-cell lung ...

Like a scene from a movie, a British beauty influencer and a German disabled war veteran could provide just the spark that ...

Although type 2 diabetes tends to get more airtime, type 1 diabetes also had drawn a number of the developers to the table. Recently winning the attention of Wall Street is SAB Biotherapeutics Inc., ...

Genetic mutations are the primary cause of most rare diseases. Although each condition affects a small fraction of the ...

Sovargen Co. Ltd. inked a $550 million license deal with Angelini Pharma SpA, granting Angelini development and commercialization rights to SVG-105, a novel antisense oligonucleotide drug candidate in ...

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Comphya, Getinge, Johnson & Johnson, Medaxiom, MedHub-AI, Philips, Positron, SS Innovations, U.

Researchers at Heriot-Watt University received more than £475,000 ($637,000) in funding to advance clinical work on a vibroacoustic sensor which could change how eczema is diagnosed and treated.

Med-tech financings with publicly reported values totaled $23.2 billion in the first three quarters of 2025, marking an improvement over 2023 and 2024. The rebound was driven by a resurgence in IPOs ...